CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 100 enrolled
Drug / intervention
L-selenomethionine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02644707
NCT02644707Phase 4Completed
CompareCT.gov

L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial

Aristotle University Of Thessaloniki·interventional·Posted Jan 1, 2016·Updated Feb 5, 2020

In Brief

A Phase 4 clinical trial evaluating L-selenomethionine and Placebo for Autoimmune Thyroiditis. Completed, enrolled 100 participants across 1 site.

Detailed Summary

To investigate whether the supplementation of organic selenium at the "adult" dose (200 mcg per day in the form of L-selenomethionine) has a favorable impact on thyroid function, including the titer of anti-thyroid antibodies \[Anti-thyroid peroxidase (anti-TPO) and Anti-thyroglobulin (anti-Tg) antibodies\], in children and adolescents with autoimmune thyroiditis (AT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutoimmune Thyroiditis
CountriesGreece
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 1, 2016
Enrollment StartAug 1, 2014
Primary CompletionOct 1, 2016
Study CompletionAug 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.5 years ago

Interventions

L-selenomethioninedietary

The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months

Placeboother

The group will be randomized to receive placebo (control group) for 6 months